ArticleFrontiers in medicine2026
A case analysis of Gitelman syndrome complicated with Sjögren's disease.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sjögren's disease (an autoimmune exocrinopathy) and Gitelman syndrome (an autosomal recessive renal tubulopathy caused by SLC12A3 mutations) both manifest with hypokalemia. Their coexistence can significantly complicate differential diagnosis. Methods: A 62-years-old female presented with fatigue, dry mouth, and refractory hypokalemia. Immunological testing (positive antinuclear and anti-centromere protein B antibodies) and a labial gland biopsy confirmed Sjögren's disease. However, her severe hypokalemia was disproportionate to Sjögren's-induced renal tubular acidosis alone. Genetic analysis revealed compound heterozygous pathogenic mutations in SLC12A3: c.1196G > A (p.Arg399His) and c.1732G > A (p.Val578Met), confirming concurrent Gitelman syndrome. Results: Combined therapy with potassium supplementation and hydroxychloroquine successfully resolved symptoms and stabilized serum potassium levels. Conclusion: In Sjögren's disease patients with refractory hypokalemia, underlying hereditary renal tubular disorders should be suspected. Combining immunological evaluation with genetic testing is crucial to ensure accurate diagnosis and optimize management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.